Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Autoimmune liver disease.

Albert J Czaja1

  • 1Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA. czaja.albert@mayo.edu

Current Opinion in Gastroenterology
|October 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Actin-specific smooth muscle antibodies bridge adult and juvenile autoimmune hepatitis diagnosis.

JHEP reports : innovation in hepatology·2026
Same author

Autoimmune Hepatitis Treatment: Can Low-Dose Steroids Be Generalized?

Digestive diseases and sciences·2025
Same author

Cellular senescence and its pathogenic and therapeutic implications in autoimmune hepatitis.

Expert review of gastroenterology & hepatology·2024
Same author

Easy recognition and high autoimmune hepatitis specificity of smooth muscle antibodies giving an actin microfilament immunofluorescent pattern on embryonal vascular smooth muscle cells.

Clinical and experimental immunology·2024
Same author

Introducing Molecular Chaperones into the Causality and Prospective Management of Autoimmune Hepatitis.

Digestive diseases and sciences·2023
Same author

Incorporating the Molecular Mimicry of Environmental Antigens into the Causality of Autoimmune Hepatitis.

Digestive diseases and sciences·2023
Same journal

Endoscopic techniques to minimize gastroesophageal reflux during peroral endoscopic myotomy.

Current opinion in gastroenterology·2026
Same journal

Postendoscopy esophageal adenocarcinoma and neoplasia: current status and future directions.

Current opinion in gastroenterology·2026
Same journal

The complement system in inflammatory bowel disease: from early observations to emerging frontiers.

Current opinion in gastroenterology·2026
Same journal

Goblet cell-associated antigen passages in health and disease.

Current opinion in gastroenterology·2026
Same journal

Inflammatory bowel diseases 2026: form, function and therapeutic considerations for the epithelial barrier.

Current opinion in gastroenterology·2026
Same journal

Dietary protein as a regulator of colitis and colorectal cancer.

Current opinion in gastroenterology·2026
See all related articles

Autoimmune hepatitis affects all age groups similarly, requiring comparable initial treatments. Specific genetic factors and complications like thrombosis or bile duct issues do not alter the immediate prognosis for autoimmune hepatitis patients.

Area of Science:

  • Hepatology
  • Immunology
  • Genetics

Background:

  • Autoimmune hepatitis (AIH) presents with similar virulence across all age groups, from pediatric to elderly populations.
  • Certain genetic predispositions and associated conditions require specific diagnostic considerations in AIH management.

Purpose of the Study:

  • To review key aspects of autoimmune hepatitis diagnosis and management, including genetic associations, complications, and specific patient populations.
  • To highlight factors influencing prognosis and therapeutic strategies in autoimmune hepatitis.

Main Methods:

  • Literature review of studies on autoimmune hepatitis, focusing on epidemiology, genetics, clinical features, and treatment.
  • Analysis of specific diagnostic markers, genetic mutations (HFE, HLA), and associated conditions (antiphospholipid antibodies, autoimmune sclerosing cholangitis).

Related Experiment Videos

Main Results:

  • Autoimmune hepatitis exhibits consistent severity in both young and elderly patients, suggesting similar initial treatment approaches.
  • Antiphospholipid antibodies are crucial to identify in patients with a history of thrombosis or fetal loss.
  • The C282Y HFE mutation is more prevalent in AIH but lacks distinct clinical correlation.
  • Pediatric AIH may show cholangiogram abnormalities, but autoimmune sclerosing cholangitis does not impact immediate prognosis.
  • Bile duct changes can be incidental findings without clinical significance.
  • Specific HLA types (DRB1*1301) are linked to protracted Hepatitis A virus infections in South America.
  • Chemokines like interferon gamma-inducible protein 10 and increased Fas ligand transcripts suggest roles in T-cell recruitment and apoptosis in AIH pathogenesis.
  • Pregnancy is permissible in AIH patients, with cyclosporine showing potential as a first-line therapy.

Conclusions:

  • Autoimmune hepatitis requires similar initial management regardless of patient age.
  • Screening for antiphospholipid antibodies is recommended for patients with a history of thrombosis or fetal loss.
  • While genetic factors and certain biliary changes are noted, they do not fundamentally alter the immediate prognosis or treatment strategy for autoimmune hepatitis.
  • Emerging research points to specific chemokines and apoptotic pathways in disease progression, and highlights cyclosporine as a potential first-line treatment, even during pregnancy.